Hikma Pharmaceuticals
London, Ohio, United States · Biotechnology, Health Care, Manufacturing
Hikma Pharmaceuticals is a leading player in the U.S. generic drug market. The company specializes in the manufacturing of complex generics, particularly sterile injectables, aimed at addressing the growing demand for oncology and chronic-care drugs. With a significant expansion in Ohio, Hikma aims to solidify its position by leveraging AI-driven private markets for funding. The company is focused
Key facts
- Headquarters
- London, Ohio, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Private
- Website
- www.hikma.com
- Company page
Recent activity at Hikma Pharmaceuticals
- : Hikma Pharmaceuticals Appoints Rebecca Hall as Chief Financial Officer
- : Hikma Pharmaceuticals and IFC Sign $250 Million Financing Agreement to Enhance Medicine Access in MENA.
- : Hikma acquires ANDA for trametinib from Novugen
- : Hikma expands injectables capacity with acquisition of Xellia's US assets
- : Hikma Completes Acquisition Of Custopharm
Leadership
- Hana Ramadan, Vice President
- Rehab, HR Business Partner – Organizational Development
- Rebecca Hall, Chief Financial Officer
- Naoual Iken
- Kristen Dameron, Board Member
Verified email and direct lines for Hikma Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Hikma Pharmaceuticals in the news
- Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million - JobsOhio (Jun 01, 2026)
- Hikma earmarks $267M to expand pair of Ohio production sites, add 350 jobs - Fierce Pharma (Jun 08, 2026)
- Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023 - Crowell & Moring LLP (May 05, 2026)
- Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - PR Newswire (Jun 04, 2026)
- Hikma, IFC sign $250mn deal, marking a 40-year partnership driving access to quality medicines in the MENA region - International Finance Corporation (IFC) (Jul 15, 2025)
- White & Case advises joint lead managers on Hikma Pharmaceuticals’ US$500 million bond issuance - White & Case LLP (Jul 23, 2025)
- Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin - Mintz (Jun 04, 2026)
- Directors’ Deals: Hikma Pharma director eyes recovery - Financial Times (Nov 14, 2025)
Companies similar to Hikma Pharmaceuticals
- Optimi Health · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Tirupati Group · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Creapharm · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- AnHeart Therapeutics · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- YS Biopharma · Biotechnology, Health Care, Manufacturing, Pharmaceutical
About Hikma Pharmaceuticals: questions and answers
What does Hikma Pharmaceuticals do?
Hikma Pharmaceuticals is a leading player in the U.S. generic drug market. The company specializes in the manufacturing of complex generics, particularly sterile injectables, aimed at addressing the growing demand for oncology and chronic-care drugs. With a significant expansion in Ohio, Hikma aims to solidify its position by leveraging AI-driven private markets for funding. The company is focused
Where is Hikma Pharmaceuticals headquartered?
Hikma Pharmaceuticals is headquartered in London, Ohio, United States.
Who leads Hikma Pharmaceuticals?
Hana Ramadan is a Vice President at Hikma Pharmaceuticals.
What is the latest news on Hikma Pharmaceuticals?
On Sep 24, 2026, Hikma Pharmaceuticals Appoints Rebecca Hall as Chief Financial Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy